27
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin.

      Science (New York, N.Y.)
      Adolescent, Adult, Aged, Aged, 80 and over, Antibodies, Blocking, immunology, therapeutic use, Antigens, CD95, physiology, Apoptosis, Child, Dermis, pathology, Disease Progression, Epidermis, Fas Ligand Protein, Female, Humans, Immunoglobulins, Intravenous, Jurkat Cells, Keratinocytes, metabolism, Male, Membrane Glycoproteins, Middle Aged, Pilot Projects, Stevens-Johnson Syndrome, therapy

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Toxic epidermal necrolysis (TEN, Lyell's syndrome) is a severe adverse drug reaction in which keratinocytes die and large sections of epidermis separate from the dermis. Keratinocytes normally express the death receptor Fas (CD95); those from TEN patients were found to express lytically active Fas ligand (FasL). Antibodies present in pooled human intravenous immunoglobulins (IVIG) blocked Fas-mediated keratinocyte death in vitro. In a pilot study, 10 consecutive individuals with clinically and histologically confirmed TEN were treated with IVIG; disease progression was rapidly reversed and the outcome was favorable in all cases. Thus, Fas-FasL interactions are directly involved in the epidermal necrolysis of TEN, and IVIG may be an effective treatment.

          Related collections

          Author and article information

          Comments

          Comment on this article